European Psychiatry - Volume 41 - April 2017

853 / 916

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S847–S910 S849
Objectives The aim of this study was to evaluate the relationship
between sexual function and psychological symptoms in a group
of male patients with depression and anxiety disorders.
Methods From outpatients program, we consecutively recruited
a group of 46 males: 28 patients had major depression and 18
anxiety disorders. Then, we administered two self-report psycho-
metric tools to assess male sexuality, depression and anxiety, i.e.,
international index of erectile function (IIEF-15), and Depression
Anxiety Stress Scales (DASS-21). t-tests and Pearson correlations
were performed.
Results We found significantly higher score in terms of desire and
general sexual wellness in people with anxiety disorder compared
to people with depression. However, we found more significant
correlations among depressive/anxious symptomatology and sex-
ual impairment inmales with anxiety disorders compared to males
with depression.
Conclusions Our results revealed that males diagnosed with
depression show a decrease of sexual desire, as a vast part of
literature previously affirmed. On the contrary, the relationship
between psychological symptomatology and sexual dysfunction,
as the reduction of erectile function, was higher in males with anx-
iety disorders. This difference is probably due to a major iatrogenic
effect of antidepressive treatments in depressed patients, while in
anxious patients could be the psychological state, per se, the main
cause of sexual dysfunctions.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1352
Sexual dysfunction and mood
stabilizers in bipolar disorder:
A review
C. Gómez Sánchez-Lafuente ∗ eina Gonzalez ,
M. Hernandez Abellán
Hospital Universitario Virgen de la Victoria, Psychiatry, Málaga, Spain
∗ Corresponding author.
Introduction Mood stabilizers can cause many side effects.
Although many of these are well known, like thyroid and renal fail-
ure after taking lithium, sexual dysfunction side effects remains
unclear.
Methods We made a systematic computerized literature search
of clinical studies using MEDLINE, The Cochrane Library and Trip
for clinical studies of sexual dysfunction published up to December
2015.
Results Only eight relevant papers were identified. All of them
studied lithium sexual dysfunction in bipolar disorder patients.
Valproic acid, carbamazepine and lamotrigine were not studied in
patientswith bipolar disorder. Nevertheless, the threewere studied
in epilepsy. Clinical reports usually used Arizona Sexual Experience
Scale or Psychotropic Related Sexual Dysfunction Questionnaire
to measure sexual dysfunction and Brief Adherence Rating Scale
to measure medication adherence. They suggest lithium could
decrease desire and sexual thoughts, worse arousal and cause
orgasm dysfunction. In overall, those patients with sexual dysfunc-
tion had lower level of functioning and poor compliance. Taking
benzodiazepines during lithium treatment may increase the risk of
sexual dysfunction even more.
Conclusion There are few studies that focus on mood stabilizers
sexual dysfunction. This inevitably entails a number of limitations.
First, the small sample size and, in some studies, the relative short
period of follow-up may underestimate the results. Besides, prac-
tical management was not treated in any study. Actually, handling
this side effect have not been well established.
To conclude, this revision suggest that approximately 30% patients
receiving lithium experience this side effect, and it is associated
with poor medication adherence.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1353
Sexuality of Tunisian women with
polycystic ovary syndrome
N. Halouani∗ llouze , R. Naoui , J. Aloulou , O. Amami
Hédi Chaker University Hospital, psychiatry, Sfax, Tunisia
∗ Corresponding author.
Introduction The polycystic ovary syndrome (PCOS) is a het-
erogeneous disease with multiple facets. In a few decades, this
syndrome has gone from a purely gynaecological domain to sexol-
ogy one; PCOS is thus considered a systemic disease. However, the
domain of sexuality continues to be neglected. The aimof our study
was: assessing women’s sexuality with PCOS by comparing them
to a sample correlated with the age of control subjects. We per-
formed a cross-sectional study of case-control, conducted between
October and November 2015.
Data was collected by oral questionnaire proposed to women
whose anonymity was respected. To assess the sexuality we used
the “female sexual function index” (FSFI) developed by Rosen et al.
Results The average BMI of the patients was 30.2 ± 6.3 kg/m2,
with a range of 17.2 to 43.5 kg/m2. The average frequency of sex-
ual intercourse per week was 1.6 ±0.5 for patients and 2.1 ±0.9 for
the controls. The scores used in this study show that 90% of sex-
ual dysfunction exists in women with PCOS For controls, a sexual
dysfunction was found in 40% of cases.
All aspects of sexuality were affected (desire, arousal, orgasm and
satisfaction). The lowest scores were found in the following areas:
arousal, lubrication and orgasm.
Conclusion The therapist during a consultation for a patient with
PCOS should check her psychological state. Also, asking the patient
about her sex life should be part of the monitoring of the disease.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1354
Methylation of the HPA axis related
genes in men with hypersexual
disorder
J. Jokinen
Umeå University, Clinical Sciences, Umeå, Sweden
Introduction Hypersexual disorder (HD) defined as non-
paraphilic sexual desire disorder with components of impulsivity,
compulsivity and behavioral addiction, was proposed as a diagnosis
in the DSM-5. Recent research shows some overlapping features
between HD and substance use disorder including common
neurotransmitter systems and dysregulated hypothalamic-
pituitary-adrenal (HPA) axis function. We have reported that HD
was significantly associated to DST non-suppression and higher
plasma DST-ACTH levels indicating HPA axis dysregulation in male
patients with HD.
In this cohort, comprising 54 male patients diagnosed with HD and
33 healthy male volunteers, we aimed to identify HPA-axis cou-
pled CpG-sites, in which modifications of the epigenetic profile are
associated with hypersexuality.
Methods We performed multiple linear regression models of
methylation M-values to a categorical variable of hypersexuality
in 87 male subjects, adjusting for depression, DST non-suppression
status, CTQ total score, and plasma levels of TNF-alpha and IL-6.
Results Seventy-six individual CpG sites were tested, and four
of these were nominally significant (P < 0.05), associated with
the genes CRH, CRHR2 and NR3C1. Cg23409074–located 48 bp